Resolution of the Council of Experts “Results of a multicenter, randomized, double-blind, placebo-controlled study of ARTNEO in patients with stage II–III primary knee osteoarthritis”-Reference-Cited by-同舟云学术

Resolution of the Council of Experts “Results of a multicenter, randomized, double-blind, placebo-controlled study of ARTNEO in patients with stage II–III primary knee osteoarthritis”

Published:2023-12-21 Issue:6 Volume:17 Page:136-142
ISSN:2310-158X
Container-title:Modern Rheumatology Journal
language:
Short-container-title:Sovremennaâ revmatologiâ

Author:

Lila A. M.¹^ORCID,Alekseeva L. I.¹^ORCID,Belyaeva I. B.²^ORCID,Vinogradova I. B.³^ORCID,Demidova N. A.⁴^ORCID,Kalyuzhin O. V.⁵^ORCID,Nesterovich I. I.⁶^ORCID,Sorotskaya V. N.⁷^ORCID,Shirokova L. Yu.⁸^ORCID,Yakupova S. P.⁹^ORCID

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

2. North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia

3. Ulyanovsk Regional Clinical Hospital

4. Pirogov Russian National Research Medical University, Ministry of Health of Russia

5. I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

6. Pavlov First Saint-Petersburg State Medical University (Pavlov University), Ministry of Health of Russia

7. Tula State University, Medical Institute

8. Yaroslavl State Medical University, Ministry of Health of Russia

9. Kazan State Medical University, Ministry of Health of Russia

Abstract

On August 31,2023 in V.A. Nasonova Research Institute of Rheumatology a meeting of the Expert Council was held at which the principal investigators and co-investigators of the ARTNEO-2021 protocol "Multicenter randomized double-blind, placebo-controlled study of ARTNEO in patients with stage II-III primary knee osteoarthritis" was held. A consensus position was developed on the possibility and feasibility of using a combination of undenatured (native) type II collagen, methylsulfonylmethane, boswellic acids, vitamins C and D (ARTNEO complex) in clinical practice. Based on the results of the study, the use of the ARTNEO complex can be recommended as part of a complex therapy for patients with osteoarthritis as a course treatment with total duration up to 6 months. The results of the study can only be interpreted in relation to ARTNEO and cannot be transferred to preparations with a different composition.

Publisher

IMA Press, LLC

Subject

Pharmacology (medical),Immunology,Immunology and Allergy,Rheumatology

Reference30 articles.

1. Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023 Feb 3;8(1):56. doi: 10.1038/s41392-023-01330-w.

2. Hawker GA, King LK. The Burden of Osteoarthritis in Older Adults. Clin Geriatr Med. 2022 May;38(2):181-192. doi: 10.1016/j.cger.2021.11.005.

3. Favero M, Belluzzi E, Ortolan A, et al. Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 2022 Mar;18(3): 171-183. doi: 10.1038/s41584-021-00747-3. Epub 2022 Feb 1.

4. Conaghan PG, Abraham L, Graham-Clarke P, et al. OP0190 Understanding current prescription drug treatment paradigms for patients with osteoarthritis in Europe. Ann Rheum Dis. 2020;79:118.

5. Namba RS, Inacio MC, Pratt NL, et al. Postoperative opioid use as an early indication of total hip arthroplasty failure. Acta Orthop. 2016 Jul;87 Suppl 1(Suppl 1):37-43. doi: 10.1080/17453674.2016.1181820. Epub 2016 May 11.